Amy Heimberger, MD, professor in the Department of Neurosurgery, University of Texas MD Anderson Cancer Center, talks about immunotheraputics in the context of glioblastoma (GBM).
Amy Heimberger, MD, professor in the Department of Neurosurgery, University of Texas MD Anderson Cancer Center, talks about immunotheraputics in the context of glioblastoma (GBM). Heimberger says the mechanisms that glioblastoma tumors use for suppression are much more heterogenous than other tumors. She said because of this, oncologists are now studying the effects of targeted the key hubs of tumor-mediated immune suppression.
Heimberger says one target of interest for oncologists is in the secreted protein FGL2. FGL2 is secreted by GBM and regulated several mechanisms of immune suppression. Heimberger says that by targeting FGL2, treatment could be more significant for GBM patients.
Combining Avutometinib With Defactinib Yields High Response Rates in LGSOC
March 22nd 2024In heavily pretreated patients with recurrent low-grade serous ovarian cancer, the combination of avutometinib plus defactinib showing promising results within the phase 2 ENGOT-ov60/GOG-3052/RAMP 201 trial.
Read More
FDA Grants Fast Track Designation to MVR-T3011 in HNSCC
March 20th 2024The FDA fast-tracked MVR-T3011, an intratumorally injected oncolytic virus, for treating recurrent or metastatic head and neck squamous cell cancer post-platinum chemotherapy and at least 1 prior anti-PD1/PDL1 therapy.
Read More